Categories
Cannabinoids Cannabis Oils Cannabis Plant CEO & Collaborators Hemp Oil Industrial Hemp Medical

Human Studies on Cannabidiol as a Treatment for Anxiety

Medical research shown shown that a chemical produced by the cannabis sativa plant reduces anxiety. This constituent of cannabis is called cannabidiol, or just CBD.

Cannabis has many constituents, but by far the most well known is tetrahydrocannabinol, or THC, the constituent which gets the user ‘high’. CBD however, has completely different effects from THC and is becoming more and more popular as multiple studies suggest that this substance is an anxiolytic, which means that it reduces anxiety and panic. CBD also diminushed the psychoactivity of THC, meaning that it can helps people that are using medical marrijuana to counter the unwanted “high” associate with THC present in that treatments.

CBD was discovered in 1940 by Dr. Roger Adams at the University of Illinois. At that time, cannabis was only known for its psychotropic constituent THC, so studies were mainly focused there. As a result, there was little done to explore and study the effects of CBD for many years. More recently, studies on CBD have been done first on animals and then on humans to determine exactly what CBD does in the body. Medicine has discovered that CBD does have many medicinal benefits, and we are starting to hear about them.

One of the pioneer study in 1993 compared CBD with Ipsapirone, diazepam and a placebo. Ipsapirone is an anxiolytic drug often used in research. Diazepam is a drug used to reduce anxiety in patients by working on chemicals in the brain that are unbalanced in people who suffer from anxiety. The study tested the different drugs and CBD on a set of healthy people. The subjects were subjected to a simulated public speaking test in order to create a stressful environment in which scientists could verify if CBD was anxiolytic. By measuring subjects’ heart ratea, blood pressure and skin conductance, the study showed that only Ipsapirone decreased anxiety during public speaking, CBD decreased anxiety that occurred after the test, and diazepam was effective before and after the test, but not during the test. The study suggested that CBD and Ipsapirone had anxiolytic properties.

A more recent study in 2004 investigated the effects of CBD on regional cerebral blood flow by doing single-photon emission computed tomography (SPECT) scans on the subjects. This scan gives doctors three pieces of information: areas of the brain that work well, areas of the brain that are low in activity, and areas that are high in activity. Doctors can then determine if the subject needs specific medicine to regulate certain areas that need to be balanced. Since in this case study, the test itself was stressful, it was a good way to test CBD. The results showed that CBD reduced anxiety, according to blood flow, and was compatible with regular blood flow.

In more than one study, it was also discovered that the effects of dosage levels act in a U-shaped curve. Small dosages of 100mg of CBD were ineffective, dosages of 300mg to 600mg were most effective and treatments over 900mg of CBD were also ineffective.

In 2009, another study made the use of functional magnetic resonance imaging (FMRI), which produces more images with higher resolution and gives a clearer image of the levels of activity in the brain, to see if CBD had anxiolytic effects. They tested 15 healthy people and the results showed that CBD did reduce the anxiety caused by the stress of the FMRI.

A Brazilian study done in 2010 found that Cannabidiol has therapeutic potential with antipsychotic, anxiolytic, and antidepressant properties, in addition to being effective in treating other conditions on subjects with psychiatric disorders and in healthy subjects. These findings suggest that CBD may be effective is treating patients with anxiety as a mental illness.

 

Categories
Cannabis Plant In the News Industrial Hemp Latest News

Industrial Hemp: Senate’s 2018 Farm Bill Makes Way for Economic Growth

After 77 years of heavy restrictions by the federal government, industrial hemp is inching closer to becoming just like any other commodity crop. It’s been a long road and the battle is still not over but on June 28th the Senate took a major step forward and passed legislation legalizing hemp as part of the 2018 Farm Bill.

The bill includes all the language from Mitch McConnell’s, (R-KY), Hemp Farming Act, which was just introduced in April of this year with the help of Senators Ron Wyden, Rand Paul and Jeff Merkley. The House farm bill also passed on June 21st so now with the passing of the Senate’s version, the permanent legalization of hemp is one step closer to becoming reality.

There are still some steps left in the process but Leader McConnell and the array of bi-partisan supporters should secure that it is signed into law soon. That would mean that hemp would finally be permanently removed from the purview of the Controlled Substances Act. The Farm Bill would also give states the chance to become primary regulators of hemp production as well as allow hemp researchers to apply for competitive federal grants from the U.S Department of Agriculture. In addition, hemp farmers would also be eligible for crop insurance. Following a bi-partisan 86-11 vote, McConnell praised the passage of the bill and added, “Consumers across America buy hundreds of millions in retail products every year that contain hemp, but due to outdated federal regulations that do not sufficiently distinguish this industrial crop from its illicit cousin, American farmers have been mostly unable to meet that demand themselves. It’s left consumers with little choice but to buy imported hemp products from foreign-produced hemp.”

Of course there is never going to be a federal bill that pleases everyone. During the committee markup, Senator Charles Grassley (R-IA), one of Congress’s most staunch opponents of this law reform, threatened to challenge the current bill’s hemp provisions on the floor. Namely he wanted to remove the legalization of derivatives of the cannabis plant, such as cannabidiol (CBD), which is used by many people for medicinal purposes. But Grassley never ended up filing a floor amendment avoiding what would have been a contentious debate by hemp supporters. Overall the bill represents a solid effort by lawmakers as well as a timely one- bills are updated about every 5 years and the current one, the Agricultural Act of 2014, will soon expire.

The fundamentals of this Farm Bill rests squarely on the new, proposed definition of “hemp”, which explicitly adds cannabinoids and other derivatives to the definition and requires that hemp contain no more than 0.3% THC.

With the passing of this bill, the Senate seems serious about ensuring the future of American agriculture as well as strengthening the safety measures that directly help commodity producers. Here are some of the many benefits the new Farm Bill would have on the hemp industry:

  • Allow hemp production in all states- even those that have not yet acted to allow it
  • Remove newly defined hemp from the controlled substances list
  • Authorize CBD extraction from hemp flowers
  • Include U.S. grown hemp in the USDA National Organic Program
  • Open the door to research opportunities
  • Allow access to public water rights for hemp farmers
  • Fund safety net programs for farmers
  • Allow access to federal programs like crop insurance and low interest loans
  • Permit hemp production on tribal land and in Puerto Rico
  • Remove restrictions on intellectual property protection
  • Lower the adjusted gross income threshold at which farmers are no longer eligible for farm subsidies from $900,00 to $700,000

 

While there is no definitive timeline- the bill still needs to be merged with a competing version from the House before a final version can be sent to the White House for President Trump’s signature- hemp has broad bipartisan support and legalization is clearly on the horizon. The legalizing of hemp nationwide will finally end decades of bad policymaking and open up economic opportunities for many farmers across the country. There are high hopes for this bi-partisan legislation; many believe it could play a key role in the economic future of this nation by reversing damaging environmental trends, creating more jobs and bringing vitality back to rural farming communities. And that’s a good thing- especially for an industry that’s been in a major slump for 30 years.

 

Categories
Cannabis Oils Cannabis Plant Hemp Oil In the News Industrial Hemp Latest News Marketing Press Releases Top Stories

Earth Science Tech Announces Highly Anticipated New Revamp Industrial Hemp Products Launch Date & Forecasts Highest Grossing Month

Doral, FL, February 8, 2018 (GLOBE NEWSWIRE) – Earth Science Tech (OTC PINK: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announces launch date on the Company’s highly anticipated new revamp industrial hemp products and forecasts highest grossing month.

Monday, February 12, 2018 is the official launch dat foe the Company’s highly anticipated High Grade Full Spectrum Cannabinoids new revamp products and marketing strategy, announced early December 2017.

High Grade Full Spectrum Cannabinoids is composed of Netherland CO2 supercritical extracted organically grown unfiltered industrial hemp. The Company originally was planning on using American industrial hemp but, was able to secure a reliable high quality source in Europe to continue offering European industrial hemp causing the slight delay in launching. ETST will be one of the first companies to market it’s industrial hemp product as a Cannabinoid Complex, disclosing the mgs of each Cannabinoid, (CBD, CBDV, CBG, CBC, CBN, & CBDA). Cannabinoid complex is naturally occurring in the 7% CBD industrial hemp plant used and is rich in Terpenes, and Saponins as well. Mixed, bottled,  and packaged in the U.S. at a CGMP facility, the Company’s High Grade Full Spectrum Cannabinoids offer the highest consistent quality that current end users trust and carry forward. Preorders are being accepted online.

Since the announcement last year on our new revamp, Mr. Checkout distributor launched last week, and new veteran Chef Sales Officer, (CSO), the exponential demand has the Company forecast the highest revenue month to date. The Company currently has new chain stores, clinics, and health shops eagerly waiting for the launch to place their orders.

Nickolas S. Tabraue, ETST’s president, director and COO concludes, “the feedback alone  the visual have been positively overwhelming. Thanks to our new CSO our sales effective growing sales team along with our CLO’s product education guidance we look have a grand presence domestically and truly stand out in the CBD industry. I would like to update our stakeholders that our audit looks to be done by the end of next week followed by the Tier II Reg A+ submission and plan on announcing completion as well as other materials progress ”

About Earth Science Tech (ETST): Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.

To learn more and to buy CBD Hemp Oil, please visit: www.earthsciencetech.com

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.EarthSciencePharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.CannabisThera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.KannaBidioiDInc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305) 546-7640

Earth Science Tech Nickolas S. Tabraue, P/D/COO (305) 615-2118

Categories
Cannabis Oils Hemp Oil In the News Industrial Hemp Latest News Marketing Press Releases

Earth Science Tech Announces Launch Dates & Forecasts for Highly-Anticipated, Revamped Industrial Hemp Products

Doral, FL, Feb. 08, 2018 (GLOBE NEWSWIRE) — Earth Science Tech (OTC PINK: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announced launch date for the Company’s highly-anticipated, revamped industrial hemp Cannabidiol (CBD) products, which lead to forecast updates reflecting to a record-high monthly revenue.

February 13, 2018 is the official launch date for the Company’s highly anticipated High Grade Full Spectrum Cannabinoids product, and corresponding marketing strategy, announced early December 2017.

High Grade Full Spectrum Cannabinoids is composed of European CO2, supercritical extracted, organically grown, and unfiltered industrial hemp. The Company was originally planning on using American industrial hemp but was able to secure a reliable high-quality source in Europe to continue offering European industrial hemp, which led to slight delays from the original launch time frame. ETST will be one of the first companies to market its industrial hemp product as a Cannabinoid Complex instead of CBD, disclosing the milligrams (mg) of each Cannabinoid (CBD, CBDV, CBG, CBC, CBN, & CBDA). Cannabinoid complex is naturally occurring in the industrial hemp plant used, and is rich in Terpenes, and Saponins. Mixed, bottled, and packaged in the U.S. at a CGMP facility, the Company’s High Grade Full Spectrum Cannabinoids offer the highest therapeutic quality that current end-users trust and carry forward. Preorders are currently being accepted online.

Since last year’s announcement on product and marketing strategy revamp, Mr. Checkout distributor launched last week, and new veteran Chef Sales Officer, (CSO), the exponential demand increase has led the Company to revise forecasts to reflect what is anticipated to be the highest revenue month to date. The Company has new chain stores, clinics, and health shops eagerly waiting for the official launch to place their initial orders.

Nickolas S. Tabraue, ETST’s president, director and COO concludes, “Between appointing a new Chief Sales Officer, launching revamped industrial hemp products with fresh branding and marketing strategies, and our new distributor Mr. Checkout, we are on track for a record-setting revenue month. We’ve made clear that we intend to make 2018 our breakout year, and we are laying a strong foundation in this first quarter. We will continue to provide updates on our material events as we can.”

“While much of the up-listing and Reg A+ offering processes are out of our hands, we want to reassure our shareholders that we have worked hard to prepare the required paperwork for our audit and offering filings. We are prioritizing transparency and creating lasting value for our stakeholders and are committed to up-listing to the QB tier of the OTC Markets this year. We will provide updates as progress is made.”